



Tel. : +32 (0)2 778 01 00  
Fax : +32 (0)2 771 56 56  
www.bdo.be

The Corporate Village  
Da Vincilaan 9 - Box E.6  
Elsinore Building  
B-1935 Zaventem

## **THROMBOGENICS NV**

**Statutory auditor's report  
to the general meeting  
of the company for the year  
ended 31 December 2017**

***Free Translation  
The original report is in Dutch***

*Free translation*  
*The original report is in Dutch*

## **Statutory auditor's report to the general meeting of the company ThromboGenics NV for the year ended 31 December 2017**

In the context of the statutory audit of the annual accounts of ThromboGenics NV (the Company), we hereby present our statutory auditor's report. It includes our report on the audit of the annual accounts as well as our report on the other legal and regulatory requirements. These reports form part of an integrated whole and are indivisible.

We have been appointed as statutory auditor by the general meeting of 3 May 2016, following the proposal formulated by the board of directors, based on the advice of the audit committee. Our statutory auditor's mandate expires on the date of the general meeting deliberating on the annual accounts closed on 31 December 2018. We performed the statutory audit of the annual accounts of the company ThromboGenics NV for eight consecutive years.

### **Report on the audit of the annual accounts**

#### ***Unqualified opinion***

We have audited the annual accounts of the Company, which comprise the balance sheet as at 31 December 2017, the profit and loss account for the year then ended and notes to the annual accounts, with a balance sheet total of 154.077.823,04 EUR and a profit and loss account showing a profit for the year of 23.823.553,73 EUR.

In our opinion, the annual accounts give a true and fair view of the Company's net equity and financial position as at 31 December 2017, as well as of its results for the year then ended, in accordance with the financial reporting framework applicable in Belgium.

#### ***Basis for unqualified opinion***

We conducted our audit in accordance with International Standards on Auditing (ISAs) as applicable in Belgium. Our responsibilities under those standards are further described in the 'Statutory auditor's responsibilities for the audit of the annual accounts' section in this report. We have complied with all the ethical requirements that are relevant to the audit of annual accounts in Belgium, including those concerning independence.

We have obtained from the board of directors and company officials the explanations and information necessary for performing our audit.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Key audit matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the annual accounts of the current year. These matters were addressed in the context of our audit of the annual accounts as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

- **Impact of agreement with Alcon/Novartis**

#### *Discussion of the matter*

As a result of an agreement made in 2017, Alcon/Novartis paid a cash amount of 53.7 million EUR and did an equity investment of 10 million EUR in the beginning of 2018 in return for the recovery by Thrombogenics of its global rights to its product JETREA (ocriplasmin).

This transaction was significant to our audit procedures, because of its important financial impact on the annual accounts.

#### *Procedures performed*

Our audit procedures included, amongst others:

- We have analyzed the agreement to create an understanding of the impact on the financial statements and its disclosures.
- We reviewed the accounting treatment as presented by the management, and in particular the revenues recognized in line with the valuation rules.

- **Impairment of assets**

#### *Discussion of the matter*

The intangible fixed assets include capitalized development costs relating to JETREA® sVMA/VMT. These fixed assets are amortized on a yearly basis over their estimated economical lifetime, and an additional impairment was already recorded in 2016. Triggered by impairment indicators at the end of 2017, the company tested these assets for impairment. This impairment test did not result in the need for an additional impairment, since the carrying value did not materially deviate from the realizable value.

The valuation of these intangible assets is significant to our audit because of the potential significant impact on the financial statements and the fact that the impairment test contains key judgmental areas that are strongly affected by assumptions.

#### *Procedures performed*

Our audit procedures included, among others:

- We have analyzed and reviewed the Company's impairment model including the significant underlying assumptions and checked whether an adequate valuation model was applied.
- We have assessed whether the cash generating units were correctly defined.
- We consulted a valuation expert in our firm to assess the methodology and discount rate as applied in the model.

- We reviewed the sensitivity analysis prepared by management to understand the effect of changing assumptions.
- We considered all available information provided to us by the Company to assess potential additional impairment triggers.

#### ***Responsibilities of the board of directors for the annual accounts***

The board of directors is responsible for the preparation of annual accounts that give a true and fair view in accordance with the financial reporting framework applicable in Belgium, and for such internal control as the board of directors determines is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts, the board of directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the board of directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

#### ***Statutory auditor's responsibilities for the audit of the annual accounts***

Our objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue a statutory auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control;
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the board of directors;
- Conclude on the appropriateness of the board of directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our statutory auditor's report to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify our

opinion. Our conclusions are based on the audit evidence obtained up to the date of our statutory auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern;

- Evaluate the overall presentation, structure and content of the annual accounts and whether the annual accounts represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit as well as significant audit findings, including any significant deficiencies in internal control that we have identified during our audit.

We also provide the Audit Committee with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and, where applicable, related safeguards.

From the matters communicated with the Audit Committee, we determine those matters that were of most significance in the audit of the annual accounts of the current year, and are therefore the key audit matters. We describe these matters in our statutory auditor's report unless law or regulation precludes public disclosure about the matter.

#### **Report on other legal and regulatory requirements**

##### ***Responsibilities of the board of directors***

The board of directors is responsible for the preparation and the content of the management report as well as for compliance with the legal and regulatory requirements regarding bookkeeping, with the Company Code and with the Company's by-laws.

##### ***Responsibilities of the statutory auditor***

In the context of our mandate and in accordance with the Belgian standard (Revised in 2018) which is complementary to the International Standards on Auditing (ISAs) as applicable in Belgium, it is our responsibility to verify, in all material aspects, the management report and compliance with certain provisions of the Company Code and of the Company's by-laws, as well as to report on these elements.

##### ***Aspects related to the management report***

In our opinion, after having performed specific procedures in relation to the management report, the management report is consistent with the annual accounts for the same same financial year, and it is prepared in accordance with articles 95 and 96 of the Company Code.

In the context of our audit of the annual accounts, we are also responsible for considering, in particular based on the knowledge we have obtained during the audit, whether the management report contains any material misstatements, i.e. any information which is inadequately disclosed or otherwise misleading. Based on the procedures we have performed, there are no material misstatements we have to report to you.

We do not express any form of assurance whatsoever on the management report.

***Statement related to the social balance sheet***

The social balance sheet, to be deposited at the National Bank of Belgium in accordance with article 100, § 1, 6°/2 of the Company Code, includes, both in terms of form and content, the information required by the said Code, and does not present any material inconsistencies with the information that we have at our disposition during the performance of our mandate.

***Statement related to independence***

- Our audit firm and our network did not provide services which are incompatible with the statutory audit of annual accounts, and we remained independent of the Company throughout the course of our mandate.
- The fees related to additional services which are compatible with the statutory audit of annual accounts as referred to in article 134 of the Company Code were duly itemised and valued in the notes to the annual accounts.

***Other statements***

- Without prejudice to certain formal aspects of minor importance, the accounting records are maintained in accordance with the legal and regulatory requirements applicable in Belgium.
- The appropriation of results proposed to the general meeting complies with the legal provisions and the Company's by-laws.
- There are no transactions undertaken or decisions taken in breach of the by-laws or of the Company Code that we have to report to you.
- This report is in compliance with the contents of our additional report to the Audit Committee as referred to in article 11 of Regulation (EU) No 537/2014.
- In accordance with article 523 of the Company Code, we are also required to report to you on the following transactions which have taken place:
  - On 11 September 2017 the Board has discussed the warrant plan 2017. ViBio BVBA, represented by its permanent representative, Mr Patrik De Haes (CEO) has stated that he had a conflict of interest in accordance with article 523 of the Belgian Company Code for the approval of warrants that have been granted to him and therefore did not take part in the deliberation and decision making. The financial consequences of this decision cannot be quantified yet.
  - On the Board of 7 December 2017 Patrik De Haes and Paul Howes declared that they had a conflict of interests within the meaning of article 523 of the Belgian Company Code with regard the achievement of the 2017 corporate objectives. Patrik De Haes is the permanent representative of ViBio BVBA which serves as CEO of the Company. Paul Howes serves as President of ThromboGenics, Inc. As executive members of the BoD, both individuals are entitled to receive an annual variable compensation. The amount of the variable compensation is dependent on the BoD's assessment of the

achievement of the corporate objectives and its resolution about the pay-out ratio for the variable compensation. The financial consequences cannot be determined yet.

Zaventem, 30 March 2018



BDO Réviseurs d'Entreprises Soc. Civ. SCRL  
Statutory auditor  
Represented by Gert Claes